Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.70 |
| ▸ | RET | P07949 | 7/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.70 |
| ▸ | KIT | P10721 | 4/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.70 |
| ▸ | FLT1 | P17948 | 3/20 | 0.70 |
| ▸ | FLT4 | P35916 | 3/20 | 0.70 |
| ▸ | ABL1 | P00519 | 3/20 | 0.70 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.70 |
| ▸ | STK10 | O94804 | 2/20 | 0.70 |
| ▸ | BCR | P11274 | 2/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.70 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.70 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.70 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.70 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.70 |
| ▸ | ERN1 | O75460 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1889974 | 0.92 | PDGFRA (0.62) | KDRRETPDGFRAAURKBKIT | |
| SCHEMBL22535160 | 0.92 | PDGFRA (0.65) | KDRRETPDGFRAAURKBKIT | |
| SCHEMBL22535112 | 0.92 | KDR (0.59) | KDRRETPDGFRAAURKBKIT | |
| SCHEMBL22535152 | 0.91 | PDGFRA (0.61) | KDRRETPDGFRAAURKBKIT | |
| SCHEMBL1892785 | 0.90 | PDGFRA (0.62) | KDRRETPDGFRAAURKBKIT | |
| SCHEMBL1890089 | 0.90 | KDR (0.77) | KDRRETPDGFRAAURKBKIT | |
| SCHEMBL1895557 | 0.90 | KDR (0.57) | KDRRETPDGFRAAURKBKIT | |
| SCHEMBL1890694 | 0.90 | PDGFRA (0.61) | KDRRETPDGFRAAURKBKIT | |
| SCHEMBL2177590 | 0.89 | KDR (0.76) | KDRRETPDGFRAAURKBKIT | |
| SCHEMBL23366513 | 0.88 | KDR (0.83) | KDRRETPDGFRAAURKBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117380121-B | Production process and safe production system of lenvatinib mesylate | 安徽尖峰北卡药业有限公司 | 2024-05-14 | — | — | CN | claimed |
| CN-117380121-A | Production process and safe production system of lenvatinib mesylate | 安徽尖峰北卡药业有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117380121-B | Production process and safe production system of lenvatinib mesylate | 安徽尖峰北卡药业有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117380121-A | Production process and safe production system of lenvatinib mesylate | 安徽尖峰北卡药业有限公司 | 2024-01-12 | — | — | CN | disclosed |
| EP-4089076-A1 | HIGH-PURITY QUINOLINE DERIVATIVE AND METHOD FOR MANUFACTURING SAME | Eisai R&D Management Co., Ltd. (JP) | 2022-11-16 | — | — | EP | disclosed |
| EP-4089076-A1 | HIGH-PURITY QUINOLINE DERIVATIVE AND METHOD FOR MANUFACTURING SAME | Eisai R&D Management Co., Ltd. (JP) | 2022-11-16 | — | — | EP | disclosed |
| US-20220048862-A1 | High-Purity Quinoline Derivative and Method for Manufacturing Same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-02-17 | — | — | US | disclosed |
| US-20220048862-A1 | High-Purity Quinoline Derivative and Method for Manufacturing Same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-02-17 | — | — | US | disclosed |
| US-11186547-B2 | High-purity quinoline derivative and method for manufacturing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-30 | — | — | US | disclosed |
| US-11186547-B2 | High-purity quinoline derivative and method for manufacturing same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-30 | — | — | US | disclosed |
| CN-113683564-A | High-purity quinoline derivative and process for producing the same | 卫材R&D管理有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-1415987-B1 | NITROGENOUS AROMATIC RING COMPOUNDS AS ANTI CANCER AGENTS | EISAI R&D MAN CO LTD (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20070004773-A1 | Amorphous salt of 4-(3-chiloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1698623-A1 | CRYSTAL OF SALT OF 4-(3-CHLORO-4-(CYCLOPROPYLAMINOCARBONYL)AMINO-PHENOXY)-7-METHOXY-6-QUINOLINECARBOXAMIDE OR OF SOLVATE THEREOF AND PROCESSES FOR PRODUCING THESE | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20040253205-A1 | c-Kit kinase inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | KDR 22/4885RET 1681/4885PDGFRA 1572/4885 |
| US-20220048862-A1 | High-Purity Quinoline Derivative and Method for Manufacturing Same | NQO2, ABL1, KCNQ2 | KDR 4634/4885RET 4331/4885PDGFRA 3584/4885 |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | KDR 60/4885RET 2461/4885PDGFRA 1743/4885 |
| US-20070004773-A1 | Amorphous salt of 4-(3-chiloro-4-(cycloproplylaminocarbonyl)aminophenoxy)-7-method-6-quinolinecarboxamide and process for preparing the same | CA7, CA4, CHIA | KDR 4339/4885RET 4042/4885PDGFRA 1480/4885 |
| US-11186547-B2 | High-purity quinoline derivative and method for manufacturing same | NQO2, ABL1, KCNQ2 | KDR 4634/4885RET 4331/4885PDGFRA 3584/4885 |
| US-20040253205-A1 | c-Kit kinase inhibitor | KIT, MASTL, TNNI3K | KDR 368/4885RET 55/4885PDGFRA 752/4885 |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | KDR 60/4885RET 2461/4885PDGFRA 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.